Trial name or title	RIS-INT-45
Methods	Allocation: random, using a central randomisation procedure. Blindness: double, no further details. Duration: 8 weeks. Design: parallel. Location: multicentre. Setting: in- and outpatient.
Participants	Diagnosis: (DSM-IV) schizophrenia, PANSS between 60 and 120. N=not reported. Sex: not reported. Age: 18-65 years. History: duration ill not reported, age at onset not reported
Interventions	1. Olanzapine: Fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N=not reported. 2. Risperidone: Fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N=not reported.
Outcomes	Safety and efficacy. Cognitive performance. Sleepiness, weight gain.
Starting date	1 April 1997
Contact information	Professor Michael Reveley Department of Psychiatry Clinical Sciences Building University of Leicester Leicester Royal Infirmary PO BOX 65 LE2 7LX United Kingdom Telephone: 0116 252 3242
Notes